OncoMatch/Clinical Trials/NCT04098744
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Is NCT04098744 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Artesunate vaginal insert for cin 2/3.
Treatment: Artesunate vaginal insert — This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: HPV any genotype
Any HPV genotype detectable by DNA test/HPV genotyping
Disease stage
Required: Stage CIN2, CIN3, CIN2/3
Excluded: Stage CERVICAL ADENOCARCINOMA IN SITU
Grade: high grade
cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2/3)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Gynecologic Oncology · Fort Myers, Florida
- University of Michigan · Ann Arbor, Michigan
- Cleveland Clinic Fairview Hospital · Cleveland, Ohio
- Cleveland Clinic Foundation · Cleveland, Ohio
- Hillcrest Hospital · Mayfield Heights, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04098744 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require HPV?
Yes, HPV any genotype is a required biomarker for enrollment.
What disease stage is eligible?
Stage CIN2 or CIN3 or CIN2/3 is required.
Is there an age limit?
Yes. Patients must be 100 years or younger and at least 25 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify